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Purpose. To assess the impact of clinical variables on social skills and behaviors in Parkinson’s disease (PD) patients and patient
versusexaminer estimatesofsocialfunctioning. Methods.Twenty-eight patientswithPDand32controlswithchronicdiseasewere
assessed with a battery of neuropsychologic, personality, mood, and social function tests. Results. Patients’ estimates of their own
social functioning were not signiﬁcantly diﬀerent from examiners’ estimates. The impact of clinical variables on social functioning
in PD revealed depression to be the strongest association of social functioning in PD on both the patient and the examiner
version of the Social Adaptation Self-Evaluation Scale. Conclusions. PD patients appear to be well aware of their social strengths
and weaknesses. Depression and motor symptom severity are signiﬁcant predictors of both self- and examiner reported social
functioning in patients with PD. Assessment and treatment of depression in patients with PD may improve social functioning and
overall quality of life.
1.Introduction
A series of recent studies suggest that patients with
Parkinson’s disease (PD) present with impairments in social
behaviors and social functioning [1–4]. Changes in the
qualityofsocialinteractions,furthermore,maypredateonset
of overt extrapyramidal motor signs of PD by several years
[5, 6]. Thus, a better understanding of the determinants of
social functioning in PD is needed.
Deﬁcits in executive cognitive functions that are often
associated with PD [7] may also inﬂuence social func-
tioning and self-monitoring of social behaviors. Speciﬁc
personality and behavioral changes are often observed in
patients with deﬁcits in frontal lobe functioning. These
personality changes include problems with behavioral disin-
hibition, apathy, disinterest, interpersonal communication,
andirritability [1,8–11].Patientswhopresentwithexecutive
deﬁcits and personality changes associated with these deﬁcits
would likely also evidence impairments in social functioning
such as those related to social interactions and empathetic
responding.
Mood and general cognitive function may also be factors
that inﬂuence social functioning. For example, patients who
are depressed often show impaired social behaviors [12]
and show improvements in a variety of social domains
after treatment with antidepressant medication [13]. It is
also likely that clinical factors such as disease severity,
moodandcognitivedysfunctionwillnegativelyimpactsocial
functioning in PD.
To date, no studies have simultaneously assessed eﬀects
of patients’ own awareness of social functioning or of the
impact of clinical, cognitive and personality variables on
socialfunctioninginPD.Inthefollowingstudy,weevaluated
social functioning in PD by simultaneously assessing the2 Parkinson’s Disease
contributionofseveralclinicalvariablestobothself-reported
and examiner-rated social behaviors (including social func-
tioning and empathy) in PD.
2. Methods
Thestud ywasappr o v edb ytheV et eransA ﬀairs(VA)Internal
Review Board for protection of human subjects. One of
the authors (Erica Harris) presented each participant with a
detailedinformedconsentagreementthatdescribedtherisks
and procedures of the study. After the participant indicated
consent and signed the form, testing began.
2.1. Participants. Twenty-eight nondemented patients with
PD (2 female) were recruited from the outpatient Movement
Disorders Clinic at the VA Boston Healthcare System,
Boston, MA. Patients were individually diagnosed by Dr.
Raymon Durso, director of the clinic. All were right-handed.
Ten patients were at Hoehn-Yahr (H-Y) Stage II and 15 at
Stage III. All patients were rated for disease severity on the
Uniﬁed Parkinson’s Disease Rating Scales (UPDRS) by a PD
specialist (Raymon Durso). All participants scored 25 and
above on the Mini-Mental State Examination [14] and none
weredementedaccordingtoclinicalexaminationsandDSM-
IV [15] criteria. All were on some form of dopaminergic
medication and were tested while on medications with
optimal eﬀects (i.e., motor signs were well controlled).
Medication information was obtained from each patient
by the neurologist and levodopa equivalent dosages were
calculatedbasedonpreviousreportswith100mglevodopa =
83mg levodopa with a COMT inhibitor = 1mgpramipexole
= 1mg pergolide [16]. Thirty-two control subjects (CS; 12
female) were also recruited from the VA community. All of
these control participants had some form of chronic disease
or medical complaint such as low back, head or neck chronic
pain syndromes. All participants with a history of substance
abuse or head injury were excluded.
3. Measures
3.1. Mood Tests. We assessed depression, stress and anxiety
with the short-form of the Depression Anxiety Stress Scales
(DASS) developed by S.H. Lovibond and P.F. Lovibond
[17]. Crawford and Henry [18]a n dA n t o n ye ta l .[ 19]
have reported excellent reliability, validity and other
psychometric properties for the three subscales of the DASS.
The test includes 21 questions, 7 in each of the depression,
anxiety and stress subscales with higher scores indicating
greater impairment. The DASS Manual [17] reports the
following cutoﬀ scores for depression (normal = 0–9, mild
= 10–13, moderate = 14–20, severe = 21–27, and extremely
severe = 28+); anxiety (normal = 0–7, mild = 8–9, moderate
= 10–14, severe = 15–19, and extremely severe = 20+),
and stress (normal = 0–14, mild = 15–18, moderate =
19–25, severe = 26–33, and extremely severe = 34+). The
DASS Manual indicates that the scores of the DASS21 are
comparable to the scores of the full length DASS but that
the scores will need to be doubled before comparison to
the cutoﬀ scores. The DASS Manual also reports Cronbach’s
alpha-coeﬃcients for each of the 3 subscales: depression =
0.81, Anxiety = 0.73 and Stress = 0.81 [17].
3.2. Stroop Color-Word Interference Procedure. To assess
executive cognitive functioning, we used the Stroop color-
word interference test. This test requires the subject to name
the color of the ink or to name the word of a color-word that
is printed [20]. An “interference” test card consists of rows
of color words printed in ink colors incongruent with the
word represented, with the task being to name the ink colors
as quickly as possible. Susceptibility to cognitive interference
is calculated as the total time taken to name the colors
and read the words. PET studies show that orbitofrontal
cortex is activated in healthy subjects during the interference
condition [21].
3.3.SocialAdaptationSelf-EvaluationScale(SASS). To quan-
titativelyassessquantityandqualityofovertsocialbehaviors,
we used the Social Adaptation Self-Evaluation Scale (SASS).
TheSASS[13]isa21-itemquestionnairethatisadministered
to patients (SASS-P) to obtain self-ratings about behavior
and motivation. A virtually identical version of the question-
naire is provided to the examiner or to a signiﬁcant other
(SASS-E) to ﬁll out with respect to the patient. The items
target speciﬁc types of social behavior. We required the rater
to rate the quality of those behaviors and if they occur at all.
“Quality” refers to how well the social behavior is adapted
to social context and how well the behavior accomplishes
intendedgoalsofthepatient.Ratingsforeachsocialbehavior
range from 0–3 (0 = no, 1 = minimal, 2 = medium, and
3 = maximal social adjustment). The minimum score for
both the self-report and examiner versions of the scale is
0 and the maximum score is 60. Higher scores indicate
greater adaptation to the social environment. Using this
scale, “normal” social functioning was determined to be a
score of 35–52; therefore, impaired functioning is any score
below 35. The SASS evidences good face validity, internal
and external validity, test-retest reliability, and a Cronbach’s
alpha-coeﬃcient of 0.74 for all individual items [13].
3.4. Empathy Quotient. The ability to empathize with
another is a core social ability as it allows one to take
the perspective of another in any given social exchange.
To assess interpersonal empathy ability, we administered an
empathy scale devised by Baron-Cohen and Wheelwright,
The Cambridge Behaviour Scale [22]. It contains a total of
60 self-report statements with only 40 of those statements
tapping empathy and the remaining 20 statements acting as
ﬁllers. About half of the statements were worded to produce
disagree responses so that biased responding sets could be
checked. The empathy scale yields an “empathy quotient”, or
EQ. The minimum EQ score is 0 and the maximum score
is 80, with one point given if the empathic statement is
endorsed mildly (slightly agree) or two points given it if is
endorsed strongly (strongly agree). The same scoring rules
applied to those empathic statements that elicited a “stronglyParkinson’s Disease 3
Table 1: Comparison of clinical and demographic variables in CS and PD participants.
CS (n = 32) PD (n = 28) Signiﬁcance
Age 56.3 (9.2) 66.5 (11.9) P<. 0001
∗∗∗
Education 15.3 (2.7) 13.9 (3.0) ns
MMSE 28.3 (1.5) 26.6 (1.7) P<. 0001
∗∗∗
DASS—Anxiety 2.12 (2.4) 5.32 (4.1) P<. 0001
∗∗∗
DASS—Depression 3.94 (4.7) 4.32 (4.3) ns
Stroop 3 Interference 46.8 (29.8) 51.3 (29.8) ns
Disease Duration N/A 9.01 (4.96) N/A
Ha n dYS t a g e
a N/A 3 (2–3) N/A
UPDRS total N/A 25.3 (13.1) N/A
LDE N/A 628.9 (330.8) N/A
Notes: ∗∗∗P<. 0001;ns:notsigniﬁcant;N/A:notapplicable;CS:control;PD:Parkinson’sdisease;MMSE:mini-mentalstateexam;DASS:DepressionAnxiety
Stress Scales; H & Y Stage: Hoehn & Yahr Stage; UPDRS: Uniﬁed Parkinson’s Disease Rating Scale; LDE: Levodopa Dosage Equivalent.
aMedian (range) is reported.
Table 2: Comparison of CS and PD participants on SASS and EQ variables.
CS (n = 32) PD (n = 28) Signiﬁcance
SASS-P total 42.8 (10.7) 40.4 (7.6) ns
SASS-E total 44.6 (11.1) 41.4 (9.7) ns
EQ Total 40.7 (12.7) 39.3 (12.3) ns
Notes: ns: not signiﬁcant; CS: control; PD: Parkinson’s disease; SASS-P: Social Adaptation Self-Evaluation Scale, Patient version; SASS-E: Social Adaptation
Self-Evaluation Scale, Examiner version; EQ: The Cambridge Behaviour Scale, empathy quotient.
disagree” or “slightly disagree” responses [23]. Test-retest
reliability for the EQ is r = 0.97 [22].
4.StatisticalAnalyses
4.1. The Social Functioning Data in Both the CS and the
PD Participants Was Normally Distributed. Independent
student’s t-tests were performed to compare diﬀerences
between CS and PD groups on all demographic and clinical
variables as well as variables related to social functioning.
Paired-samples t-tests were performed in order to examine
diﬀerences between patient and examiner report of social
functioninginbothPDandCSgroups.Amultipleregression
analysis was performed to examine which clinical and
cognitive variables signiﬁcantly accounted for variance in
patient and examiner ratings of social functioning as well as
interpersonal empathy. The analyses were performed using
DASS-anxiety, DASS-depression, age, disease stage, disease
duration, UPDRS total, MMSE and Stroop interference as
predictors and SASS-P, SASS-E, and EQ as the criterion
variables.
5. Results
Demographic and clinical diﬀerences between PD and CS
participants are presented in Table 1. PD participants were
signiﬁcantly older, had lower MMSE scores and had higher
DASS total scores. We therefore treated these latter three
variables (age, MMSE score and mood) as covariates in all
the analyses that follow.
5.1. Overall Diﬀerences in Social Functioning and Empathy
i nP D sv e r s u sC o n t r o l s .No signiﬁcant diﬀerences in social
functioning or empathy score were found between PD and
CS participants, even when controlling for age, MMSE and
DASS total mood score (see Table 2).
5.2. Examiner versus Patient’s Ratings on the SASS. There
were no signiﬁcant diﬀerences on any of the individual SASS
itemsoronthetotalscoresbetweenexaminerandself-report
of social functioning in either PD or CS groups.
5.3. Predictors of Examiner Estimates on Patient Social
Functioning. The next set of analyses was performed to
examine the relationship of clinical variables to examiner’s
estimates of patient social functioning (see Table 3). The
overall model was signiﬁcant accounting for 73% of variance
in SASS-E score. When each variable was examined, DASS-
depression was the only signiﬁcant predictor of social
functioning in patients with PD as reported by the observers
(β =− .67,P = .002).
5.4. Predictors of Patient’s Self-Rankings on Social Behaviors.
This analysis was repeated for the patient version of the SASS
and again the overall model was signiﬁcant accounting for
75% of variance in SASS-P score (Table 3). For this version
of the SASS, DASS-depression was the strongest predictor of
patient self-rating of their social functioning (β =− .60,P =
.004) followed by UPDRS total (β =− .44,P = .04).
5.5. Predictors of Interpersonal Empathy. A third set of
multivariate regression analyses was performed to examine4 Parkinson’s Disease
Table 3: Results of multiple regression analyses of clinical variables as predictors of social functioning in patients with PD. Values presented
are the standardized coeﬃcient Beta (β)a n dP-values for SASS-E, SASS-P, and EQ.
β (P value)
SASS-E SASS-P EQ
Disease Duration −.31 ±.28 (P = .06) .16 ±.22 (P = .34) −.33 ±.48 (P = .13)
Disease Stage −.06 ±.59 (P = .66) −.12 ±.46 (P = .43) −.16 ±.83 (P = .42)
UPDRS Total −.27 ±.14 (P = .18) −.44 ±.11 (P = .04)
∗ −.38 ±.25 (P = .15)
MMSE .32 ±1.56 (P = .10) −.30 ±1.23 (P = .14) −.30 ±2.66 (P = .25)
Age −.04 ±.13 (P = .79) −.09 ±.10 (P = .60) .11 ±.22 (P = .62)
DASS Anxiety −.11 ±.46 (P = .56) −.16 ±.37 (P = .41) −.12 ±.79 (P = .65)
DASS Depression −.67 ±.42 (P = .002)
∗∗ −.60 ±.33 (P = .004)
∗∗ −.28 ±.71 (P = .27)
Stroop Interference .14 ±.07 (P = .52) −.08 ±.05 (P = .71) −.54 ±.12 (P = .08)
Notes: ∗P<. 05; ∗∗P<. 01; SASS-E: Social Adaptation Self-Evaluation Scale, Examiner version; SASS-P: Social Adaptation Self-Evaluation Scale, Patient
version; EQ: The Cambridge Behaviour Scale, empathy quotient; MMSE: mini-mental state exam; DASS: Depression Anxiety Stress Scale; UPDRS: Uniﬁed
Parkinson’s Disease Rating Scale.
the impact of the same set of clinical variables (DASS-
anxiety, DASS-depression, age, disease stage, disease dura-
tion, UPDRS total, MMSE, and Stroop interference) on the
total score on the EQ (see Table 3). These analyses revealed
that none of the above variables were signiﬁcant predictors
of the EQ score.
6. Discussion
In the current study, we found that patients with PD and
close examiners of these individuals did not diﬀer in rating
their social behaviors. PD patients appear to be well aware of
their social strengths and weaknesses. A multivariate analysis
oftheimpactofclinicalvariablesonsocialfunctioninginPD
revealed that depression is the strongest predictor of social
functioning in PD for examiner and patient-rated scores
of social functioning. In addition, an analysis of patients’
self-rating of their own social interactions also revealed that
motor symptom severity may impact social functioning in
patients with PD. None of the clinical or cognitive variables
were signiﬁcant predictors of empathy in those with PD.
These ﬁndings suggest that patients estimate their social
interaction abilities on the basis of their own experience of
diseaseseverity and theiroverallmood whilecloseexaminers
rely on observed mood states of the person with PD when
judging the quality of PD social interactions.
Social functioning requires communication of ideas and
emotions between persons involved in a social interaction.
Communicationofemotionbetweenpeoplerequiresanabil-
ity to empathize with others as well as eﬀectiveconveyanceof
visual impressions, facial displays, speech prosody patterns
and gesture, among other capacities. Our data suggest that
the ability to empathize with others appears to be intact
in persons with PD. Nevertheless, independent lines of
evidence [24–26] suggest that PD patients exhibit impaired
recognition of emotional expression in the faces of other
people. This impairment persists even after controlling for
visual discrimination deﬁcits. Other symptoms of PD such
as masked facies and dysarthria can make communication
diﬃcult and thus inﬂuence the quality and quantity of social
interactions. Crucian et al. [27] reported induction of verbal
kinesia paradoxica in some patients with PD who were asked
to recall emotional episodes. Patients could not adequately
express their memory-linked emotions. All of these facts
suggest that PD patients, particularly depressed PD patients,
may be impaired in the expression and recognition of social
emotions.
Patients with primary depression (without PD) have also
been reported to be impaired on a variety of social domains
[12]. In these patients, treatment of depression is linked
to improvement in social functioning [13]. In the current
study, we found that in patients with PD, depression was also
linked to greater impairment in social functioning. Almost
half of PD patients (45%) experience clinically signiﬁcant
levels of depression [28]. Depression in PD is not related to
the motor symptom severity or the duration of the disease
[28]. However, it signiﬁcantly reduces quality of life, and as
we document here, it impairs social interaction and social
behaviors.
Our study has limitations. We did not assess apathy
which is a common nonmotor symptom of PD that is
associatedwithreducedmotivation andreducedinitiation of
social interactions. Thus, we cannot rule out the possibility
that some of the patients had apathy and that apathy, in
addition to mood and motor deﬁcits, was inﬂuencing social
outcomes. We also used a small convenience sample, and
therefore, our participants may not be representative of the
largerPDpopulation.PDisheterogeneousinitspresentation
and a small sample may not suﬃciently represent the various
symptom proﬁles of patients in the general population.
Because of its heterogeneity, various studies have aimed to
investigate meaningful subtypes of the disease, an eﬀort that
is important for understanding the etiology of the disorder
and disease management. Due to the sample size limitation
and lack of power we were not able to analyze subgroups
of patients, which would give a more thorough examination
of the association of depression and social functioning. A
larger scale study is therefore needed to investigate this
issue more thoroughly. The current study did not include
any diagnostic measures of depression so we were not ableParkinson’s Disease 5
to examine whether patients who were clinically depressed
presented with deﬁcits in social functioning. However, our
study demonstrates that higher scores on a measure of
depression do signiﬁcantly predict lower scores on a measure
ofsocialfunctioning.Futureresearchisneededtomorethor-
oughly investigate the contribution of clinically diagnosed
depression to social functioning in PD. In addition, we did
not measure all relevant variables for an analysis of social
functioning in PD. A key aspect of social cognition is the
ability to infer other peoples’ mental states, thoughts and
feelings. This is referred to as Theory of Mind (ToM), or
mentalizing ability. We did not measure ToM abilities in our
participants so we could not assess the potential impact of
ToM performance on social skills in PD. To our knowledge,
only two studies have been published on ToM abilities in PD
[4,29].BothstudiesreportedthatPDpatientswereimpaired
on at least one ToM task.
In summary, this study suggests that both the awareness
of and social dysfunction itself in PD may be a function of
various disease-related factors such as depression and motor
symptom severity. Treating the depression may improve
social functioning and improve quality of life in these
patients. Various studies show that pramipexole improves
depression in addition to motor symptoms in patients with
PD [28]. By studying the social cognitive abilities of patients
and the relation of these to other clinical characteristics of
thedisease,wehavefortheﬁrsttimequantitativelydescribed
elements of social interaction in PD in relation to well-
deﬁnedclinicalfactors,anareapreviouslyneglectedinearlier
studies of behavioral impairment in PD.
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